Glycated Albumin Assay Market size is expected to reach US$ 504 million by 2034

US market for glycated albumin tests to grow 8.7% annually. Personalized medicine in US boosts demand for tests to manage diabetes. Market growth is driven by factors such as the increased number of diabetic patients above the age of 65 years and government initiatives for disease diagnosis. On the other hand, challenges associated with the glycated albumin assay market, like unfavorable reimbursement scenarios, are the major factors restricting market growth

NEWARK, Del, March 11, 2024 (GLOBE NEWSWIRE) — The glycated albumin assay market is expected to reach US$ 223.9 million by 2024. The market size is expected to reach US$ 504 million by 2034, projected at a CAGR of 8.4%. The glycated albumin assay is a test for quantifying glycated albumin in human serum. In diabetic patients, evaluating glucose control over the past few weeks is especially important. This test is useful when the commonly used HbA1c test fails to reflect glycemic control appropriately.

Recent improvements have aimed to improve the accuracy and reliability of glycated albumin readings. This includes developing enzymatic ways to remove endogenous glycated amino acids and peroxide, resulting in more precise readings. New glycated albumin tests have been developed and are traceable to standard reference materials. As a result, laboratories will be able to compare and compare their results.

Request A Sample Copy of This Report:

Glycated albumin is used as a short- to medium-term integrated glycemic control monitor. Being able to represent the last few weeks’ glycemic status makes it a useful tool for tracking diabetic patients’ glycemic control. Researchers have offered different experimental affinity approaches for measuring glycated albumin. These methods are intended to increase the accuracy and reliability of glycated albumin assays, especially in point-of-care testing situations.

Studies have compared glycated albumin to glycated haemoglobin (HbA1c) as glycemic management indicators. Glycated albumin has been shown to represent variations in plasma glucose over the short and postprandial periods, offering additional information to HbA1c. Novel solutions for glycated albumin monitoring have been described, along with alternative experimental affinity approaches. These approaches intend to increase the accuracy and reproducibility of glycated albumin readings, particularly in point-of-care testing (POCT) situations.

Enzymatic and immunoassay-based techniques have increased the accuracy and reliability of glycated albumin readings. These approaches provide benefits such as quicker turnaround times, sensitivity to recent glycemic changes, and independence from factors that may affect traditional glycated hemoglobin (HbA1c) testing.

Key Takeaways from the Market Study:

  • The United States is estimated to register at a CAGR of 8.7% by 2034.
  • A 13.7% CAGR was recorded between 2019 and 2023 for Japan’s market.
  • China is expected to achieve a CAGR of 9% from 2024 to 2034.
  • The type 2 diabetes segment is anticipated to expand at 8.1% CAGR by 2034.
  • Hospitals & diabetic care centers are expected to show a compound annual growth rate of 7.8% during the forecast period.

“As the healthcare sector grows and research and development investments become increasingly prevalent, they will drive demand for the glycated albumin assay market,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Request Report Methodology:

Glycated Albumin Assay Market Report Scope:

Attributes Details
Estimated Market Size in 2024 US$ 223.9 million
Projected Market Valuation in 2034 US$ 504 million
Value-based CAGR 2024 to 2034 8.4%  
Forecast Period 2024 to 2034
Historical Data Available for 2019 to 2023
Market Analysis Value in US$ million
Key Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East and Africa
Key Market Segments Covered
  • Application
  • End User
  • Region
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Poland
  • Russia
  • Czech Republic
  • Romania
  • India
  • Bangladesh
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC countries
  • South Africa
  • Israel
Key Companies Profiled
  • Asahi Kasei Pharma Corporation
  • EKF Diagnostics Holdings plc
  • Weldon Biotech India Private Limited
  • Hzymes Biotechnology Co. Ltd.
  • Beijing Strong Biotechnologies Inc.
  • Diazyme Laboratories Inc. (General Atomics)
  • Abbexa Limited
  • Biomatik Corporation
  • Abnova Corporation
  • Geno Technology Inc.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights:

Competitive Landscape:

Developing strategic partnerships can help enterprises expand output and satisfy consumer demand, which in turn increases revenue and market share. Promoting innovative products and technologies will make them profitable for users in the long run.

  • Hzymes Biotechnology Co., Ltd.: Hzymes Biotechnology, as the name implies, is most likely involved in the development of enzymes and biotechnological products. They may have experience developing assays for a variety of biomarkers, including glycated albumin.
  • Beijing Strong Biotechnologies, Inc- Beijing Strong Biotechnologies, situated in China, is most likely engaged in biotechnological research and development. They may be developing assays and diagnostic tools, such as those for assessing glycated albumin levels.
  • Diazyme Laboratories, Inc. (General Atomics)- Diazyme Laboratories specialises in the development and manufacturing of clinical diagnostic reagents. They may have diabetes tests and/or solutions for testing glycated albumin in clinical samples.

Glycated Albumin Assay – Key Segments:

By Application:

  • Type 2 Diabetes
  • Type 1 Diabetes
  • Prediabetes

By End User:

  • Hospitals & Diabetic Care Centers
  • Diagnostic Laboratories
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East and Africa

Authored By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI’s related ongoing Coverage in the Healthcare Market Insights Domain:

Blood Glucose Monitoring Devices Market Size: The blood glucose monitoring devices market size is estimated to be valued at US$ 14.2 billion in 2024. The market is estimated to cross a valuation of US$ 22.2 billion by 2034.

Diabetes Care Devices Market Share: The global diabetes care devices market size is projected to be valued at US$ 9.7 Billion in 2022 and is anticipated to reach US$ 17.87 Billion by 2032, with a rapid CAGR of 6.3% from 2022 to 2032.

Inhalation CDMO Market Growth: The global inhalation CDMO industry is expected to expand at a CAGR of 5.7% in the forecast period 2024 to 2034. The market value is projected to increase from US$ 8,639.1 million in 2024 to US$ 14,863.6 million in 2034.

Lateral Flow Assay Component Market Trends: The lateral flow assay component market is projected to be worth US$ 373.1 million in 2024. The market is anticipated to reach US$ 558.0 million by 2034. The market is further expected to surge at a CAGR of 4.1% during the forecast period 2024 to 2034.

Nucleic Acid Extraction Kit Market Demand: Exhibiting a Y-o-Y growth of 8.1%, the global nucleic acid extraction kit market size is projected to reach US$ 2,134.40 million in 2024. It will likely register rapid growth, with global nucleic acid extraction kit demand rising at a CAGR of 7.4%. By 2034, the global market valuation is set to total US$ 4,285.08 million.

Oligonucleotide API Market Opportunity: Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 5.60% from 2024 to 2034. As such, the global oligonucleotide API market is projected to increase from a valuation of US$ 2.81 billion in 2024 to US$ 4.84 billion by the end of 2034.

Handheld Ultrasound Scanner Market Forecast: The global handheld ultrasound scanner market size is anticipated to be worth US$ 750.3 million by 2034. According to the estimates, the market is projected to clock a 3.90% CAGR until 2034. In 2024, the handheld ultrasound scanner market size is valued at US$ 511.8 million.

Tattoo Removal Laser Market Outlook: The tattoo removal laser market size is estimated to be worth US$ 247.4 million in 2024. The rise in tattoo popularity over recent years has led to a corresponding increase in the demand for tattoo removal services. The demand for tattoo removal lasers is predicted to rise at a CAGR of 4.30% through 2034. The tattoo removal laser industry is anticipated to surpass US$ 376.8 million by 2034.

Medical Face Shield Market Overview: The medical face shield market is anticipated to be worth US$ 517.9 million in 2024. The market is expected to register at a rate of CAGR 4.6% through 2034. By the end of the forecast period, the market value is predicted to hit US$ 812.0 million.

Optical Imaging Market Development: The optical imaging market share is estimated to show consistent growth throughout the forecast period, expanding at a CAGR of 4.7%. The optical imaging market value is expected to expand from US$ 1,465.4 million in 2024 to US$ 2,319.6 million by 2034.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
LinkedInTwitterBlogs | YouTube

Primary Logo

Originally published at